-
Merck and Moderna Launch Phase III Study for Individualized Neoantigen Therapy in Lung Cancer
•
US pharmaceutical companies Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) and Moderna Inc. (NASDAQ: MRNA) have initiated the Phase III INTerpath-009 study to evaluate V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab). The study will focus on patients with resectable Stage…
-
Moderna Inc. Announces Cost-Cutting Measures and Pipeline Realignment
•
Moderna Inc. (NASDAQ: MRNA), a leading mRNA technology company based in the U.S., has announced a strategic realignment during its investor R&D day, reflecting a broader trend among multinational corporations (MNCs) to streamline operations. The company has committed to a program that includes cost-cutting measures and a reprioritization of its…
-
Carisma Therapeutics and Moderna Expand Partnership to Target Autoimmune Diseases with CAR-M Therapies
•
Carisma Therapeutics Inc. (NASDAQ: CARM), a U.S.-based company specializing in chimeric antigen receptor (CAR) macrophage therapies, has announced an expansion of its collaboration with fellow U.S. firm Moderna Inc. (NASDAQ: MRNA). This strategic partnership extension will focus on the development of in vivo CAR macrophage and monocyte (CAR-M) therapies for…
-
GSK Enters into Strategic Partnership with Flagship Pioneering to Develop Novel Medicines and Vaccines
•
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has announced a new partnership with Flagship Pioneering, a biotech company based in Cambridge, Massachusetts, known for its role as a bioplatform for innovation across a diverse portfolio of over 40 companies. The collaboration will see an initial joint funding of…
-
Moderna Partners with Mitsubishi Tanabe for mRNA Vaccine Promotion in Japan
•
Moderna Inc. (NASDAQ: MRNA), a leading mRNA specialist biotechnology company based in the U.S., has selected Japan’s Mitsubishi Tanabe Pharmaceutical Corp. to establish a co-promotion partnership for Moderna’s mRNA respiratory vaccine portfolio in the Japanese market. The agreement will encompass the promotion of Moderna’s COVID-19 vaccine, Spikevax, and aims to…
-
Moderna’s RSV Vaccine Efficacy Wanes to 50% After 18 Months, Shares Slide
•
Moderna Inc. (NASDAQ: MRNA), a U.S.-based biopharmaceutical company, has announced long-term efficacy data for its recently approved respiratory syncytial virus (RSV) vaccine, mResvia, showing a decline in effectiveness to approximately 50% after 18 months. This is notably lower than the efficacy rates of RSV vaccines from competitors GSK and Pfizer,…
-
Moderna Initiates Construction of First China-Based Pharmaceutical Plant in Shanghai
•
S-based mRNA specialist, Moderna (NASDAQ: MRNA), has commenced construction on its inaugural pharmaceutical facility in China, as reported by Xinhua. The new plant, situated in Shanghai’s Minhang District at the Xinzhuang Industry Park, is set to serve as Moderna’s China R&D and production headquarters. The project has attracted an investment…
-
CARsgen Therapeutics Partners with Moderna to Combine CAR-T Therapy with mRNA Cancer Vaccine
•
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced a collaboration agreement with US mRNA giant Moderna Inc. (NASDAQ: MRNA). The partnership aims to investigate the use of CARsgen’s investigational Claudin18.2 (CLDN18.2)-targeted chimeric antigen receptor (CAR) T-cell product candidate, CT041, in combination with Moderna’s investigational CLDN18.2 mRNA cancer vaccine. Combining…
-
GSK’s RSV Vaccine Arexvy Launches in US Pharmacies Ahead of 2023/24 Season
•
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has announced that its respiratory syncytial virus (RSV) vaccine, Arexvy, is now available at all major pharmacies in the US. The vaccine received approval in the country earlier this year and was subsequently recommended by the Advisory Committee on Immunization Practices (ACIP)…
-
Moderna Announces Immunogenicity of Updated COVID-19 Vaccine Against New Variants
•
Moderna (NASDAQ: MRNA) has announced preliminary data indicating that an updated version of its SARS-CoV-2 vaccine is immunogenic against the EG.5 and FL.1.5.1 variants, recently renamed Eris and Fornax by the World Health Organization (WHO), with Eris being classified as a variant of interest (VOI). This development marks a significant…
-
Pfizer and Flagship Pioneering Invest $100 Million in Drug Candidates Development
•
Global pharmaceutical giant Pfizer (NYSE: PFE) and venture capital firm Flagship Pioneering have this week announced a joint commitment to invest USD 50 million each into the development of 10 drug candidates. Pfizer retains the option to acquire these candidates, while Flagship stands to collect up to USD 700 million…
-
Pfizer Launches Phase III Trial for Quadrivalent Influenza modRNA Vaccine in Argentina
•
Global pharmaceutical giant Pfizer (NYSE: PFE) has commenced recruitment in Argentina for a Phase III clinical trial evaluating the efficacy of its quadrivalent influenza modified RNA (modRNA) vaccine in comparison to a conventional quadrivalent influenza vaccine. This double-blind study aims to recruit between 1,500 to 2,000 participants who are above…
-
Harbour BioMed Reports First-Ever Profit in H1 2023 Interim Financial Results
•
Harbour BioMed (HKG: 2142), a biotech company with operations in Suzhou, China, Cambridge in the US, and the Netherlands, has announced its interim financial results for the period ending June 30, 2023. In a preliminary review of unaudited figures, the company reported a net profit for the first time, expecting…
-
Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology
•
US-based vaccine manufacturer Moderna (NASDAQ: MRNA) has registered a new subsidiary in the Minhang district of Shanghai with an investment of USD 100 million. The new unit is controlled by Moderna Biotech UK, and the legal representative is Christoph Brackmann, Moderna’s vice-president of finance, as reported by a local media…
-
Nona Biosciences Licenses HCAb Technology to Dragonfly Therapeutics
•
Nona Biosciences, a newly established wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck a licensing deal with US firm Dragonfly Therapeutics. The agreement grants Dragonfly rights to use Nona Bio’s heavy chain only antibody discovery platform (HCAb) technology and develop antibodies according to Dragonfly’s designated targets. Financial details…
-
Harbour BioMed and Moderna Ink Licensing Deal for Oncology Immunotherapies
•
Harbour BioMed (HKG: 2142), a biotech company with operations in the United States, the Netherlands, and Suzhou, China, has announced a licensing agreement between its wholly owned subsidiary Nona Biosciences and US mRNA specialist ModernaTX, Inc. (NASDAQ: MRNA). The collaboration will focus on discovering and developing nucleic acid-based immunotherapies for…
-
Moderna’s CMO Expresses Eagerness to Bring mRNA Vaccines to China
•
The Chief Medical Officer (CMO) of US-based Moderna Inc. (NASDAQ: MRNA), Paul Burton, has been reported as saying that the company is “eager” to bring its mRNA-based COVID-19 vaccines to China. According to sources, Moderna’s chief executive Stephane Bancel disclosed last week that the company has engaged in talks with…
